MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

Core Insights - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [2] - The company is developing two key products: DA-1726 for obesity and vanoglipel for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [2] Product Development - DA-1726 is a novel oxyntomodulin (OXM) analogue acting as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), showing best-in-class potential for weight loss, glucose control, and waist reduction in Phase 1 trials [2] - Vanoglipel is a G-protein-coupled receptor 119 (GPR119) agonist that enhances the release of gut peptides GLP-1, GIP, and PYY, demonstrating positive effects on liver inflammation, lipid metabolism, and glucose control in pre-clinical studies and Phase 2a clinical studies [2] Conference Participation - MetaVia will participate in and sponsor the 10th Annual MASH-TAG 2026 Conference from January 8-10, 2026, in Park City, Utah, with members from its business development and clinical teams attending [1]